Crinetics CCO James Hassard to depart effective October 14, 2024

Crinetics Pharmaceuticals, Inc.

James Hassard separates as Chief Commercial Officer; last day October 14, 2024.
Hassard will receive severance per Employment Agreement for termination without cause, subject to release.
No replacement for CCO role announced by Crinetics.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

James Hassard

Chief Commercial Officer

CRNX · Crinetics Pharmaceuticals, Inc.

Effective: 2024-10-14
Filed: September 17, 2024, 7:59 PM ET

On September 13, 2024, Crinetics Pharmaceuticals, Inc. (the “Company”) determined that James Hassard will separate from the Company and will cease serving as the Chief Commercial Officer, effective October 14, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

James Hassard departed as Chief Commercial Officer at Crinetics Pharmaceuticals, Inc..

Action: separated
Role: Chief Commercial Officer

Exact text from the filing

On September 13, 2024, Crinetics Pharmaceuticals, Inc. (the “Company”) determined that James Hassard will separate from the Company and will cease serving as the Chief Commercial Officer, effective October 14, 2024.

View on SEC.gov

Crinetics Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-107259

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.